WilmerHale Advises Repare Therapeutics on Worldwide License and Collaboration Agreement with Roche

WilmerHale Advises Repare Therapeutics on Worldwide License and Collaboration Agreement with Roche

Client News
On June 1, 2022, Repare Therapeutics, a leading clinical-stage precision oncology company, announced it has entered into a worldwide license and collaboration agreement with Roche.

The agreement is for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase).

Under the terms of the agreement, Repare will receive a $125 million upfront payment, and is eligible to receive up to $1.2 billion in potential clinical, regulatory, commercial and sales milestones, including up to $55 million in potential near-term payments, and royalties on global net sales ranging from high-single-digits to high-teens.

The WilmerHale team advising Repare Therapeutics was led by Steven Barrett and Mat Trachok.